相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: a mini review
X. Sun et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2022)
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases
Yun Liu et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Sheng Liu et al.
PROTEIN & CELL (2021)
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Erez N. Baruch et al.
SCIENCE (2021)
Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors
Chiaki Kurimoto et al.
CANCER SCIENCE (2020)
Management of Immunotherapy-Related Toxicities, Version 1.2020 Featured Updates to the NCCN Guidelines
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Gut microbiota-derived metabolites as key actors in inflammatory bowel disease
Aonghus Lavelle et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Signaling networks in immunometabolism
Jordy Saravia et al.
CELL RESEARCH (2020)
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
Nicolas Palaskas et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
The Gut Microbiota: Emerging Evidence in Autoimmune Diseases
Xuan Zhang et al.
TRENDS IN MOLECULAR MEDICINE (2020)
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne M. Luoma et al.
CELL (2020)
Immune checkpoint inhibitor-associated celiac disease
Yousef Badran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Neurologic autoimmunity and immune checkpoint inhibitors
Elia Sechi et al.
NEUROLOGY (2020)
Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients
Francesco Sabbatino et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis
Zsofia D. Drobni et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
CYTOKINE CHANGES DURING IMMUNE-RELATED ADVERSE EVENTS AND STEROID TREATMENT IN MELANOMA PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS
Kevin Tyan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
Quentin Scanvion et al.
ONCOIMMUNOLOGY (2020)
Metabolic coordination of T cell quiescence and activation
Nicole M. Chapman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Dysregulated Lung Commensal Bacteria Drive Interleukin-17B Production to Promote Pulmonary Fibrosis through Their Outer Membrane Vesicles
Daping Yang et al.
IMMUNITY (2019)
Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).
Rika Kizawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The pathogenicity of Th17 cells in autoimmune diseases
Keiko Yasuda et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Myasthenia Gravis Induced by Immune Checkpoint Inhibitors
Ondine Becquart et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy
Anastasia Zekeridou et al.
MAYO CLINIC PROCEEDINGS (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions
Francesca Romana Merlotti et al.
FRONTIERS IN IMMUNOLOGY (2019)
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
Alexander Faje et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Karthik Suresh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Immuno-oncology drug development goes global
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
A case of checkpoint inhibitor-induced celiac disease
Dana Alsaadi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Cytokines in Inflammatory Disease
Shinwan Kany et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
Khashayar Esfahani et al.
NATURE COMMUNICATIONS (2019)
Fine-Tuning Cytokine Signals
Jian-Xin Lin et al.
Annual Review of Immunology (2019)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y. Lim et al.
CLINICAL CANCER RESEARCH (2019)
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Omar Hasan Ali et al.
EUROPEAN JOURNAL OF CANCER (2019)
Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review
J. Pierrard et al.
CURRENT ONCOLOGY (2019)
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
Emma C. de Moel et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
Isabella Lupi et al.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS (2019)
Cytokine-mediated communication: a quantitative appraisal of immune complexity
Gregoire Altan-Bonnet et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors
Heinz Laubli et al.
ONCOIMMUNOLOGY (2018)
Safety Profile of Avelumab in Patients With Advanced Solid Tumors: A Pooled Analysis of Data From the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials
Karen Kelly et al.
CANCER (2018)
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
Adriana T. Lopez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ke Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
David Y. Oh et al.
CANCER RESEARCH (2017)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
S. Cuzzubbo et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H. June et al.
NATURE MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis
Teruaki Nakatsuji et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Guillermo De Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Farhad Seif et al.
CELL COMMUNICATION AND SIGNALING (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade
Elizabeth H. Byrne et al.
CANCER (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis
O. Abdel-Rahman et al.
CLINICAL ONCOLOGY (2016)
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer
Seiichi Ikeda et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Sumit K. Subudhi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Gut microbiota, metabolites and host immunity
Michelle G. Rooks et al.
NATURE REVIEWS IMMUNOLOGY (2016)
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging
Andras Perl
COMPANION DIAGNOSTICS: FROM BIOMARKER IDENTIFICATION TO MARKET ENTRY (2015)
Innate Immune Recognition of Cancer
Seng-Ryong Woo et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
The expanding family of regulatory B cells
Claudia Mauri et al.
INTERNATIONAL IMMUNOLOGY (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
PD-L1(hi) B cells are critical regulators of humoral immunity
Adnan R. Khan et al.
NATURE COMMUNICATIONS (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
mTOR signaling, Tregs and immune modulation
Nicole M. Chapman et al.
IMMUNOTHERAPY (2014)
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Hye Sun Kuehn et al.
SCIENCE (2014)
Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.
Katja Schindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Treg/Th17 Cell Balance: A New Paradigm for Autoimmunity
Eli M. Eisenstein et al.
PEDIATRIC RESEARCH (2009)
Cytokines and their relationship to the symptoms and outcome of cancer
Bostjan Seruga et al.
NATURE REVIEWS CANCER (2008)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
分享论文
